LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aktien・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Geschlossen

1.14 0.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	418K -5.5M
EPS	-0.18
Gewinnspanne	-6,600
Angestellte	25
EBITDA	525K -5.7M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+417.24% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-628K 37M
Vorheriger Eröffnungskurs	0.26
Vorheriger Schlusskurs	1.14

Actinium Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Mai 2026, 21:33 UTC

Ergebnisse

Correction to Salesforce 1Q Sales, Profit Rise Article

27. Mai 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. Mai 2026, 20:18 UTC

Ergebnisse

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. Mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. Mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. Mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. Mai 2026, 21:29 UTC

Heiße Aktien

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. Mai 2026, 21:08 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. Mai 2026, 21:02 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. Mai 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. Mai 2026, 20:55 UTC

Ergebnisse

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Mai 2026, 20:48 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. Mai 2026, 20:45 UTC

Ergebnisse

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. Mai 2026, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Webster Financial Stockholders Approve Sale to Banco Santander

27. Mai 2026, 20:32 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. Mai 2026, 20:30 UTC

Ergebnisse

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. Mai 2026, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. Mai 2026, 20:22 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:16 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. Mai 2026, 20:13 UTC

Ergebnisse

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer-Vergleich

Kursveränderung

Actinium Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

417.24% Vorteil

12-Monats-Prognose

Durchschnitt 6 USD 417.24%

Hoch 9 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Actinium Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Actinium Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.